Free tool
FAERS Monitor: Rybelsus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213182 or its brand name (Rybelsus, Semaglutide). Reports on generic versions are filed under their own applications.
Reports
7,735
Serious
4,368
56% of reports
Hospitalization
1,786
Death reported
180
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,110
- vomiting769
- diarrhoea614
- off label use484
- decreased appetite465
- constipation443
- blood glucose increased372
- weight decreased365
- impaired gastric emptying345
- headache325
- fatigue313
- dizziness305
- abdominal pain299
- abdominal pain upper286
- asthenia242
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 487 |
| 2021 | 841 |
| 2022 | 1,038 |
| 2023 | 1,065 |
| 2024 | 1,519 |
| 2025 | 1,570 |
| 2026 | 1,203 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,424 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| impaired gastric emptyingSignal | 345 | 70.6 | 63.6 | 23,012 |
| constipationSignal | 443 | 5.5 | 5.1 | 1,654 |
| decreased appetiteSignal | 465 | 5.5 | 5.0 | 1,702 |
| blood glucose increasedSignal | 372 | 5.4 | 4.9 | 1,331 |
| vomitingSignal | 769 | 4.5 | 4.2 | 2,099 |
| nauseaSignal | 1,110 | 3.8 | 3.6 | 2,392 |
| abdominal pain upperSignal | 286 | 3.8 | 3.4 | 587 |
| weight decreasedSignal | 365 | 3.6 | 3.2 | 677 |
| abdominal painSignal | 299 | 3.5 | 3.1 | 536 |
| diarrhoeaSignal | 614 | 2.6 | 2.4 | 615 |
| asthenia | 242 | 1.8 | 1.5 | 78 |
| dizziness | 305 | 1.7 | 1.5 | 82 |
| off label use | 484 | 1.5 | 1.4 | 85 |
| headache | 325 | 1.4 | 1.3 | 39 |
| fatigue | 313 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.